Article
Real-world Safety and Effectiveness of 24-week Sofosbuvir and Ribavirin Treatment in Patients Infected with Rare Chronic Hepatitis C Virus Genotypes 3, 4, 5, or 6 in Japan.
Internal medicine (Tokyo, Japan) - 15 May 2023
Mita Eiji, Liu Lauren J, Shing Danielle, Force Lindsey, Aoki Kouji, Nakamoto Daisuke, Ishizaki Akinobu, Konishi Hiroki, Mizutani Hajime, Ng Leslie J
Abstract excerpt
Objectives Real-world evidence on the safety and effectiveness of direct-acting antivirals in patients infected with chronic hepatitis C virus (HCV) genotypes (GTs) 3, 4, 5, or 6 in Japan is limited. This prospective observational study assesses the real-world safety profile and treatment effectiveness among patients prescribed sofosbuvir with ribavirin (SOF+RBV) for HCV GT3-6 infection in Japan. Methods Adults...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.